US — TechCrunch
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
AI1 min read
Isomorphic Labs, an AI drug-discovery company spun out of Google's DeepMind, has raised $5 billion. The money will help it move its drug candidates into human clinical trials.
A big new funding round
Isomorphic Labs raised $5 billion in a Series C round. Greenoaks and Sequoia Capital led the round, and Andreessen Horowitz joined as a new investor. All of the company's existing backers also put in more money. The company says the funds will go toward building its drug-design tools and exploring more kinds of medicine.
Key facts
- The new round is $5 billion.
- The company raised $2.1 billion in a Series B round in May.
- Bloomberg reported earlier this month that the company was seeking a $50 billion valuation. Isomorphic did not say what its new valuation is.
- The company says its program has produced "positive preclinical results" in oncology (cancer) and immunology (the immune system).
What the company does
Isomorphic Labs uses AI to design new drugs. Its system runs many simulation AI models that test different areas of chemistry. The company builds on AlphaFold, a DeepMind AI that predicts the 3D shape of proteins from their genetic sequence. Its founder, Demis Hassabis, and John Jumper won the Nobel Prize in chemistry for the AlphaFold work. The company has deals with drug makers Eli Lilly, Novartis, and Johnson & Johnson.
Why it matters
Most new drugs fail before they reach patients. Using AI to design drugs faster could save time and money. Moving drug candidates into clinical trials is a big step, because trials test whether a medicine is safe and works in people.
What to watch
- Whether Isomorphic starts clinical trials for its drug candidates.
- How its partnerships with Eli Lilly, Novartis, and Johnson & Johnson develop.
- Whether the company shares its new valuation.
- Which new types of medicine the company moves into.
Glossary
- Isomorphic Labs
- An AI company that designs new drugs using computer models.
- DeepMind
- A Google-owned AI research lab that built AlphaFold.
- AlphaFold
- An AI system that predicts the 3D shape of proteins from their genetic sequence.
- Series C
- A later round of funding where investors put money into a startup to help it grow.